Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2025 07:00 ET | Source: Comanche Biopharma

Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia

Comanche Biopharma announces European Medicines Agency (EMA) has granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated preterm preeclampsia.
January 30, 2025 05:00 ET | Source: Comanche Biopharma

Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia

Comanche awarded Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway Steering Group for CBP-4888 to treat preeclampasia.
January 17, 2024 06:00 ET | Source: Comanche Biopharma

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.